Risk Factors for Mortality in Patients with Acinetobacter baumannii Bacteremia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Se Yoon | - |
dc.contributor.author | Choo, Jin Woo | - |
dc.contributor.author | Kwon, Soon Ha | - |
dc.contributor.author | Yu, Shi Nae | - |
dc.contributor.author | Lee, Eun Jung | - |
dc.contributor.author | Kim, Tae Hyong | - |
dc.contributor.author | Choo, Eun Ju | - |
dc.contributor.author | Jeon, Min Huok | - |
dc.date.accessioned | 2021-08-12T00:46:58Z | - |
dc.date.available | 2021-08-12T00:46:58Z | - |
dc.date.issued | 2013-09 | - |
dc.identifier.issn | 2093-2340 | - |
dc.identifier.issn | 2092-6448 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13418 | - |
dc.description.abstract | Background: Acinetobacter baumannii, an opportunistic nosocomial pathogen that can cause significant morbidity and mortality, has emerged as a worldwide problem. The aim of this study was to evaluate the risk factors for mortality in patients with A. baumannii bacteremia. Materials and Methods: We retrospectively evaluated 118 patients who had A. baumannii bacteremia between July 2003 and December 2011. The aim of this study was to identify the 30-day mortality in patients with A. baumannii bacteremia and relevant risk factors. Results: The bacteremia-related 30-day mortality rate was 34.1%. Univariate analysis revealed that the risk factors for mortality included malignancy, longer hospital stay before bacteremia, intensive care unit (ICU) stay at the time of bacteremia, mechanical ventilation, use of a central venous catheter, unknown origin of bacteremia, bacteremia due to pneumonia, antimicrobial resistance to carbapenems, and elevated Acute Physiology and Chronic Health Evaluation II and Pitt bacteremia scores. Multivariate logistic regression analysis revealed that resistance to carbapenems (odds ratio [OR]: 4.01, 95% confidence interval [CI]: 1.51 to 0.68, P = 0.005), need for mechanical ventilation (OR: 3.97, 95% CI: 1.41 to 11.13, P = 0.005), and presence of malignancy (OR: 4.40, 95% CI: 1.60 to 12.08, P = 0.004) were significantly related to mortality risk. Conclusions: Risk factors such as resistance to carbapenems, mechanical ventilation, and presence of malignancy were found to be associated with high mortality rates in the patients with A. baumannii bacteremia. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy | - |
dc.title | Risk Factors for Mortality in Patients with Acinetobacter baumannii Bacteremia | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3947/ic.2013.45.3.325 | - |
dc.identifier.scopusid | 2-s2.0-84887518737 | - |
dc.identifier.wosid | 000421551100009 | - |
dc.identifier.bibliographicCitation | Infection and Chemotherapy, v.45, no.3, pp 325 - 330 | - |
dc.citation.title | Infection and Chemotherapy | - |
dc.citation.volume | 45 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 325 | - |
dc.citation.endPage | 330 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001806740 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.subject.keywordAuthor | Acinetobacter baumannii | - |
dc.subject.keywordAuthor | Bacteremia | - |
dc.subject.keywordAuthor | Mortality | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.